167 related articles for article (PubMed ID: 36644397)
1. ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe.
Heyza JR; Ekinci E; Lindquist J; Lei W; Yunker C; Vinothkumar V; Rowbotham R; Polin L; Snider NG; Van Buren E; Watza D; Back JB; Chen W; Mamdani H; Schwartz AG; Turchi JJ; Bepler G; Patrick SM
NAR Cancer; 2023 Mar; 5(1):zcac045. PubMed ID: 36644397
[TBL] [Abstract][Full Text] [Related]
2. ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
Mesquita KA; Alabdullah M; Griffin M; Toss MS; Fatah TMAA; Alblihy A; Moseley P; Chan SYT; Rakha EA; Madhusudan S
Gynecol Oncol; 2019 May; 153(2):416-424. PubMed ID: 30797591
[TBL] [Abstract][Full Text] [Related]
3. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.
Postel-Vinay S; Bajrami I; Friboulet L; Elliott R; Fontebasso Y; Dorvault N; Olaussen KA; André F; Soria JC; Lord CJ; Ashworth A
Oncogene; 2013 Nov; 32(47):5377-87. PubMed ID: 23934192
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
Cheng H; Zhang Z; Borczuk A; Powell CA; Balajee AS; Lieberman HB; Halmos B
Carcinogenesis; 2013 Apr; 34(4):739-49. PubMed ID: 23275151
[TBL] [Abstract][Full Text] [Related]
6. Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer.
Heyza JR; Lei W; Watza D; Zhang H; Chen W; Back JB; Schwartz AG; Bepler G; Patrick SM
Clin Cancer Res; 2019 Apr; 25(8):2523-2536. PubMed ID: 30538112
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle-Mediated Gene Silencing for Sensitization of Lung Cancer to Cisplatin Therapy.
Feldmann DP; Heyza J; Zimmermann CM; Patrick SM; Merkel OM
Molecules; 2020 Apr; 25(8):. PubMed ID: 32344513
[TBL] [Abstract][Full Text] [Related]
8. RPA activates the XPF-ERCC1 endonuclease to initiate processing of DNA interstrand crosslinks.
Abdullah UB; McGouran JF; Brolih S; Ptchelkine D; El-Sagheer AH; Brown T; McHugh PJ
EMBO J; 2017 Jul; 36(14):2047-2060. PubMed ID: 28607004
[TBL] [Abstract][Full Text] [Related]
9. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
Heyza JR; Arora S; Zhang H; Conner KL; Lei W; Floyd AM; Deshmukh RR; Sarver J; Trabbic CJ; Erhardt P; Chan TH; Dou QP; Patrick SM
Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400270
[TBL] [Abstract][Full Text] [Related]
10. Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy.
Ganzinelli M; Linardou H; Alvisi MF; Caiola E; Lo Russo G; Cecere FL; Bettini AC; Psyrri A; Milella M; Rulli E; Fabbri A; De Maglie M; Romanelli P; Murray S; Broggini M; Marabese M; Garassino MC
ESMO Open; 2021 Feb; 6(1):100034. PubMed ID: 33422766
[TBL] [Abstract][Full Text] [Related]
11. Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors.
Turchick A; Zimmermann A; Chiu LY; Dahmen H; Elenbaas B; Zenke FT; Blaukat A; Vassilev LT
Mol Cancer Ther; 2023 Jul; 22(7):859-872. PubMed ID: 37079339
[TBL] [Abstract][Full Text] [Related]
12. ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency.
Mohni KN; Kavanaugh GM; Cortez D
Cancer Res; 2014 May; 74(10):2835-45. PubMed ID: 24662920
[TBL] [Abstract][Full Text] [Related]
13. AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors.
Ramkumar K; Stewart CA; Cargill KR; Della Corte CM; Wang Q; Shen L; Diao L; Cardnell RJ; Peng DH; Rodriguez BL; Fan YH; Heymach JV; Wang J; Gay CM; Gibbons DL; Byers LA
Mol Cancer Res; 2021 Mar; 19(3):485-497. PubMed ID: 33172976
[TBL] [Abstract][Full Text] [Related]
14. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.
McNeil EM; Melton DW
Nucleic Acids Res; 2012 Nov; 40(20):9990-10004. PubMed ID: 22941649
[TBL] [Abstract][Full Text] [Related]
15. Computational Characterization of Small Molecules Binding to the Human XPF Active Site and Virtual Screening to Identify Potential New DNA Repair Inhibitors Targeting the ERCC1-XPF Endonuclease.
Gentile F; Barakat KH; Tuszynski JA
Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29710850
[TBL] [Abstract][Full Text] [Related]
16. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells.
Schoonen PM; Kok YP; Wierenga E; Bakker B; Foijer F; Spierings DCJ; van Vugt MATM
Mol Oncol; 2019 Nov; 13(11):2422-2440. PubMed ID: 31529615
[TBL] [Abstract][Full Text] [Related]
17. Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein-protein interaction.
Gentile F; Elmenoufy AH; Ciniero G; Jay D; Karimi-Busheri F; Barakat KH; Weinfeld M; West FG; Tuszynski JA
Chem Biol Drug Des; 2020 Apr; 95(4):460-471. PubMed ID: 31891209
[TBL] [Abstract][Full Text] [Related]
18. Loss of NEIL3 DNA glycosylase markedly increases replication associated double strand breaks and enhances sensitivity to ATR inhibitor in glioblastoma cells.
Klattenhoff AW; Thakur M; Chu CS; Ray D; Habib SL; Kidane D
Oncotarget; 2017 Dec; 8(68):112942-112958. PubMed ID: 29348879
[TBL] [Abstract][Full Text] [Related]
19. Cells from ERCC1-deficient mice show increased genome instability and a reduced frequency of S-phase-dependent illegitimate chromosome exchange but a normal frequency of homologous recombination.
Melton DW; Ketchen AM; Núñez F; Bonatti-Abbondandolo S; Abbondandolo A; Squires S; Johnson RT
J Cell Sci; 1998 Feb; 111 ( Pt 3)():395-404. PubMed ID: 9427687
[TBL] [Abstract][Full Text] [Related]
20. Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts.
Guffanti F; Alvisi MF; Caiola E; Ricci F; De Maglie M; Soldati S; Ganzinelli M; Decio A; Giavazzi R; Rulli E; Damia G
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
